Bolt Biotherapeutics (NASDAQ:BOLT) COO Sells 4,909 Shares of Stock

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) COO Grant Yonehiro sold 4,909 shares of the firm’s stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $3.32, for a total transaction of $16,297.88. Following the completion of the transaction, the chief operating officer owned 24,119 shares in the company, valued at $80,075.08. This represents a 16.91% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Grant Yonehiro also recently made the following trade(s):

• On Friday, September 18th, Grant Yonehiro sold 6,850 shares of Bolt Biotherapeutics stock. The shares were sold at an average price of $3.24, for a total transaction of $22,194.00.
• On Wednesday, September 16th, Grant Yonehiro sold 1,417 shares of Bolt Biotherapeutics stock. The shares were sold at an average price of $3.77, for a total transaction of $5,342.09.

Bolt Biotherapeutics Trading Up 0.8%

Bolt Biotherapeutics stock traded up $0.03 during trading hours on Monday, reaching $3.59. The stock had a trading volume of 22,454 shares, compared to its average volume of 27,365. The stock has a market cap of $6.93 million, a PE ratio of -0.22 and a beta of 1.09. Bolt Biotherapeutics, Inc. has a 52 week low of $3.10 and a 52 week high of $7.20. The company has a debt-to-equity ratio of 1.47, a current ratio of 2.61 and a quick ratio of 2.61. The company has a fifty day simple moving average of $3.84 and a 200-day simple moving average of $4.29.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($4.57) EPS for the quarter, missing the consensus estimate of ($3.39) by ($1.18). The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.50 million. Bolt Biotherapeutics had a negative net margin of 611.47% and a negative return on equity of 126.23%. Analysts forecast that Bolt Biotherapeutics, Inc. will post -11.1 EPS for the current fiscal year.

Hedge Funds Weigh In On Bolt Biotherapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in BOLT. Nan Fung Group Holdings Ltd bought a new stake in shares of Bolt Biotherapeutics during the 2nd quarter valued at $19,250. T3 Companies LLC bought a new position in shares of Bolt Biotherapeutics in the 4th quarter worth about $208,000. Finally, Renaissance Technologies LLC lifted its position in Bolt Biotherapeutics by 40.3% during the 1st quarter. Renaissance Technologies LLC now owns 77,225 shares of the company’s stock valued at $312,000 after acquiring an additional 22,200 shares during the period. Hedge funds and other institutional investors own 86.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on BOLT shares. HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of Bolt Biotherapeutics in a research report on Thursday, May 28th. Weiss Ratings restated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a report on Friday, July 17th. Finally, Rodman & Renshaw assumed coverage on shares of Bolt Biotherapeutics in a report on Thursday, May 28th. They issued a “buy” rating and a $22.00 price target on the stock. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $14.50.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s platform is designed to stimulate the body’s innate and adaptive immune systems to recognize and attack tumor cells.

Bolt’s technology includes Boltbody™ immune-stimulating antibody conjugates, or ISACs. These therapies are intended to combine the targeting capabilities of antibodies with immune-activating components that can recruit and enhance the activity of immune cells within the tumor microenvironment.

The company’s development programs have included BDC-1001, an investigational HER2-targeted ISAC for the treatment of HER2-expressing solid tumors, and BDC-3042, an investigational antibody intended to activate macrophages through the Dectin-2 pathway.